Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Meta Expands AI Training With Employee Activity Tracking Tools 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
MORRISTOWN, N.J., March 15, 2017 -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, announced today that the Company will report financial results for the fourth quarter and year ended December 31, 2016, after the market close on Tuesday, March 28, 2017. John Sedor, Chairman and Chief Executive Officer, and Graham Miao, President and Chief Financial Officer, will host a conference call to discuss the results.
| Date: | Tuesday, March 28 | |||||
| Time: | 4:30 PM ET | |||||
| Toll free (U.S.): | 888-576-4382 | |||||
| International: | 719-457-2735 | |||||
| Conference ID: | 4228557 | |||||
| Webcast: | http://public.viavid.com/index.php?id=123412 | |||||
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its integrated Pernix sales force and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
CONTACT Investor Relations Matthew P. Duffy, 212-915-0685 LifeSci Advisors, LLC [email protected]
